Shares of Iovance Biotherapeutics surged 18.9% to $13.07 on September 29 after the company lifted its full-year 2026 revenue guidance to $410–$420 million, a $55 million jump at the midpoint from prior estimates. The catalyst is straightforward: doctors are prescribing more of the company's flagship cell therapy for advanced melanoma, and investors are repricing the stock accordingly. Iovance's $55 Million Guidance Bump Sends Shares Soaring, but Can One Cancer Therapy Carry a $5 Billion Company
Shares of Iovance Biotherapeutics rocketed 18.9% to $13.07 on September 29 after the company told investors it now expects $410–$420 million in 2026 revenue — $55 million above its prior forecast. The announcement is the starkest sign yet that the company's melanoma cell therapy is gaining traction in U.S. hospitals, but the rally raises a hard question: how much of the upside is already priced in?
A Record Quarter Forced Management's Hand. Iovance reported record Q2 product revenue of $99.3 million and has expanded its network of authorized treatment centers to roughly 100, with plans to reach at least 110 by year-end.
The revised midpoint is ~15% above the old range and implies nearly 60% annual revenue growth for 2026. Management previously guided $350–$370 million, meaning the raise signals not just a strong quarter but a sustained demand trend the company felt confident enough to formalize.
More Hospitals Mean More Patients — and a Longer Runway. Amtagvi is the first FDA-approved cell therapy that uses a patient's own immune cells to fight advanced melanoma. The expansion of treatment centers enhances accessibility. Going from ~100 to 110+ centers by December widens the funnel of eligible patients. For a therapy that must be manufactured individually for each patient, distribution infrastructure is the growth bottleneck, and Iovance is loosening it.
The Stock Is Still Cheaper Than the Numbers Suggest — With Caveats. As of September 2026, Iovance's market cap stood at roughly $4.5 billion. At the new $415 million revenue midpoint, that puts the stock at approximately 10.8× forward sales — modest by cell-therapy standards. Goldman Sachs recently resumed coverage with a Buy rating and a $15 price target , implying further room to run. But the company is still unprofitable: net income declined about 5% year-over-year , and management acknowledged that manufacturing efficiencies are still needed to "accelerate progress toward profitability."
Concentration Risk Remains the Elephant in the Room. Virtually all of Iovance's revenue comes from two products sold in one market — the U.S. The company's pipeline spans trials in cervical cancer, lung cancer, and head and neck cancers, along with next-generation engineered cell therapies , but none of those programs generate revenue today. If Amtagvi adoption plateaus or a competitor enters the melanoma space, the growth story stalls fast.
Bottom line: A $55 million guidance raise is no small thing for a mid-cap biotech, but investors buying at today's prices are betting that one therapy can keep defying expectations quarter after quarter.